Literature DB >> 1850466

Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and muscarinic receptors induced by cycloheximide.

T Nabeshima1, K Tohyama, K Murase, S Ishihara, T Kameyama, T Yamasaki, S Hatanaka, H Kojima, T Sakurai, Y Takasu.   

Abstract

The effects of N-(2,6-dimethyl-phenyl)-2-(2-oxo-1-pyrrolidinyl)-acetamide [DM-9384], a cyclic derivative of GABA, were investigated in the cycloheximide (CXM)-induced amnesia animal model using the passive avoidance task. Pre- and post-training and pre-retention test administration of DM-9384 attenuated the CXM-induced amnesia as indicated by prolongation of step-down latency. Aniracetam, another cyclic derivative of GABA, also showed antiamnesic effects. Scopolamine, a muscarinic ACh receptor antagonist, and the GABA antagonists, picrotoxin and bicuculline, all antagonized the antiamnesic effects of DM-9384. CXM decreased the number of GABAA and muscarinic ACh receptor binding sites. DM-9384 not only inhibited this effect but actually increased the latter. These results suggest that DM-9384 attenuates CXM-induced amnesia by interacting with GA-BAergic and AChergic neuronal systems and enhancing protein synthesis in the brain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850466

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats.

Authors:  K Yamada; T Tanaka; T Mamiya; T Shiotani; T Kameyama; T Nabeshima
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  A possible mechanism for improvement by a cognition-enhancer nefiracetam of spatial memory function and cAMP-mediated signal transduction system in sustained cerebral ischaemia in rats.

Authors:  Satoshi Takeo; Makiko Niimura; Keiko Miyake-Takagi; Akira Nagakura; Tomoko Fukatsu; Tsuyoshi Ando; Norio Takagi; Kouichi Tanonaka; Junko Hara
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 4.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

5.  Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat.

Authors:  S Kawajiri; K Taniguchi; T Sakurai; T Yamasaki
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice.

Authors:  E Abe; S Murai; H Saito; Y Masuda; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1992

7.  Effects of nefiracetam, DM-9384 on amnesia and decrease in choline acetyltransferase activity induced by cycloheximide.

Authors:  T Shiotani; K Tohyama; K Murase; S Ishihara; T Kameyama; T Yamasaki; S Hatanaka; H Kojima; Y Takasu; T Nabeshima
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Effects of nefiracetam on deficits in active avoidance response and hippocampal cholinergic and monoaminergic dysfunctions induced by AF64A in mice.

Authors:  E Abe; S Murai; H Saito; Y Masuda; Y Takasu; T Shiotani; H Tachizawa; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1994
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.